Until Labs

Reversible organ cryopreservation is a problem that has defeated the field for decades: vitrifying and rewarming a whole organ without lethal ice formation, fracturing, or cryoprotectant toxicity is an unsolved engineering-and-biology challenge, and while academic groups have shown progress on kidneys, no team has demonstrated a routinely transplantable, rewarmed solid organ at clinical scale — meaning Until's near-term "product" is still a deep research program, not a near-market device. Even success on organs would require years of preclinical work and then full clinical trials before any transplant use, so the $58M Series A funds a long, uncertain runway rather than imminent revenue. The whole-body reversible-cryopreservation goal that animates the mission is far more speculative still, and tethering the company's identity to it invites the same "may be scientifically impossible" skepticism that shadows all cryonics. Founded in 2024, Until is early, and >$100M raised sets a high bar of technical progress that hard-tech biology may not deliver on venture timelines; deep-tech hardware for medicine is notoriously slow, capital-hungry, and prone to milestone slippage. Competition and precedent are sobering — organ-preservation research has attracted serious academic and commercial effort for years without a breakout product. Until has the best team, the most money, and the smartest sequencing in its category; it is still betting a large sum on cracking a problem that has humbled everyone who came before.